logo
Plus   Neg
Share
Email

AstraZeneca: Lynparza Gets Orphan Drug Designation In Japan

AstraZeneca plc (AZN.L,AZN), a British-Swedish multinational pharmaceutical and biopharmaceutical company, said Thursday that Lynparza received orphan drug designation or ODD in Japan for the maintenance treatment of germline BRCA-mutated curatively unresectable pancreatic cancer.

The pharma major revealed that the orphan drug designation was on based on the Phase III POLO trial that showed Lynparza nearly doubled the time patients lived without disease progression versus placebo.

Lynparza is co-developed and co-commercialised with MSD Inc., Kenilworth, N.J., US.

Pancreatic cancer, which has the lowest survival rate of the most common cancers, is the only major cancer with a five-year survival rate below 10 percent in almost every country.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
JetBlue Airways said it will continue to block middle seats in rows where passengers are not traveling together through the July 4 holiday. JetBue will block middle seats on its Airbus aircraft, while it will block aisle seats on its smaller Embraer 190 aircraft. Customers traveling together will be allowed to sit in the middle and aisle seats. The U.S. Food and Drug Administration or FDA announced on its website that New Hoque and Sons, Inc. is recalling Radhuni Curry Powder distributed in New York City, New York due to potential Salmonella contamination. The recall was made after it was found that the finished products contained several strains of Salmonella, the company said. General Motors is reopening its plants in Mexico after it received approval from the Mexican government to restart operations in the country, according to reports. The automaker had suspended its operations in Mexico in the third week of March due to the coronavirus pandemic. GM's Mexican manufacturing facilities are important as they supply critical parts for its plants in the U.S.
Follow RTT